Bookmark and Share

Faculty

David L. Becton, M.D.

Picture of Picture ofDavid L. Becton
  • Professor, College of Medicine, Department of Pediatrics
  • Section Chief, Hematology & Oncology

Sections

  • Hematology and Oncology

Specialties

  • Hematology/Oncology

Contact Information

  • Email: BectonDavidL@uams.edu
    Phone: 501-364-1494
    Fax: 501-364-3634
    Address: Arkansas Children's Hospital
    1 Children's Way
    Little Rock, AR 72202

Education

  • B.A., Hendrix College, 1975
  • M.D., University of Arkansas for Medical Sciences, 1979

Training

  • Fellow, Hematology/Oncology, Duke University, 1982-1985

Licensure and Board Certification

  • American Board of Medical Specialties, Pediatrics, Pediatric Hematology-Oncology
  • American Board of Medical Specialties, Pediatrics, Pediatrics

Recent Honors

  • Red Sash Award, Class of 2009, 2008

Recent Publications

  • Journal Article, Ataga KI., Reid M., Ballas SK., Yasin Z., Bigelow C., James LS., Smith WR., Galacteros F., Kutlar A., Hull JH., Stocker JW., ICA-17043-10 Study Investigators. Imporovements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011 Apr; 153(1):92-104.
  • Journal Article, Glade RS., Vinson K., Becton D., Bhutta S., Buckmiller LM. Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI. Int J Pediatr Otorhinolaryngol 2010 Nov; 74(11):1221-1225.
  • Journal Article, Baker DL., Schmidt ML., Cohn SL., Maris JM., London WB., Buxton A., Stram D., Castleberry RP., Shimada H., Sandler A., Shamberger RC., Look AT., Reynolds CP., Seeger RC., Matthay KK., Children's Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010 Sep; 363(14):1313-1323.
  • Journal Article, Pollard JA., Alonzo TA., Gerbina R., Ho PA., Zeng R., Becton David L. Prevalence and prognostic significance of KIT mutations in pediatric core binding factor AML patients enrolled on serial pediatric cooperative trials for de novo AML. Blood J of Amer. Soc. Hem. 2010 March; 115(12):2372-2379.
  • Journal Article, Stine KC., Becton DL. Bleeding disorders: when is normal bleeding not normal?. J Ark Med Soc 2009 August; 106(2):40-42.
  • Journal Article, Mian A., Becton D., Blackall DP., James SH., Berman DM., Owusu JA., Turner C., Givner LB., Shetty AK. Index of suspicion. Pediatr Rev 2009 April; 30(4):139-145.
  • Journal Article, Blanchette VS., Shapiro AD., Liesner RJ., Hernandez Navarro F., Warrier I., Schroth PC., Spotts G., Ewenstein BM., rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008 Aug; 6(8):1319-26.
  • Journal Article, Leissinger CA., Becton DL., Ewing NP., Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007 May; 13(3):249-55.
  • Journal Article, Stine KC., Saylors RL., Saccente CS., Becton DL. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost 2007 Apr; 13(2):161-5.
  • Journal Article, Stine KC., Shrum D., Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol 2007 Apr; 29(4):216-21.

Recent Grant Awards

  • A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia, Incyte , AALL1521, 2016-08-01 00:00:00-2017-07-31 00:00:00
  • A Phase 2, Multicenter, Single-Arm, Open Label Study to Evaluate the Activity , Safety and Pharmacokinetics of Lenalidomide in Pediatric Subjects from 1 to 18 YO with Relapsed or refractory Acute Myeloid Leukemia, Celgene Corporation, AAML1522, 2015-10-06 00:00:00-2017-04-21 00:00:00
  • A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors, Novartis, FP16981_SUB66_01, 2015-04-06 00:00:00-2017-04-21 00:00:00
  • A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia Testing Clofarabine in a Very High Risk Stratumq, Sanofi, AALL1131, 2014-01-06 00:00:00-2017-05-31 00:00:00
  • A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents, COG, AHOD1331, 2016-03-21 00:00:00-2017-04-21 00:00:00
  • Cancer Trials Support Unit: Phase II Supplemental Payments, NCI-COG, N02-CM-62212, 2012-01-01 00:00:00-2017-04-21 00:00:00
  • COG# ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-Cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients, COG, ANHL1131, 2013-02-01 00:00:00-2017-04-21 00:00:00
  • COG- AALL1131_A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia Testing Clofarabine in the Very High Risk Stratum, COG, AALL1131, 2012-03-30 00:00:00-2017-04-21 00:00:00
  • COG: AALL1421- A dose confirmation and Pharmacokinetic study of Asparec Administered as IV infusion in children and young adults with acute lymphoblastic leukemia/lymphoblastic lymphoma following hypersensitivity to pegaspargase, COG, AALL1421, 2014-11-01 00:00:00-2017-10-31 00:00:00
  • Health Effects after Anthracycline and Radiation Therapy (HEART):Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy, COG, ALTE11C2, 2014-11-01 00:00:00-2017-04-21 00:00:00
  • NCTN: Per Case Reimbursement, NIH, FP15221_Sub148_01, 2014-03-01 00:00:00-2017-04-21 00:00:00
  • NIH COG Chair Grant: Workload Intensity, NIH, FP00015221_SUB17_01, 2012-03-01 00:00:00-2017-04-21 00:00:00
  • Risk-Stratified Randomized Phase III Testing of Blinatumomab in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL), Amgen, AALL1331, 2016-06-01 00:00:00-2017-05-31 00:00:00
  • St. Baldrick's Foundation Grant, St. Baldrick's Foundation, 2012-04-26 00:00:00-2017-04-21 00:00:00

Services and Information